Amendments to the Specification:

Please replace the paragraph beginning at page 3, line 8, with the following rewritten paragraph:

The compounds of formula (I) are deemed novel provided that ~~5,6 dihydrospiro[imidazo[1,2-b][3]benzazepine-11[11H],4'-piperidine]~~ 5,6 dihydrospiro[imidazo[2,1-b][3]benzazepine-11[11H],4'-piperidine] and pharmaceutically acceptable addition salts thereof are not included and thus the present invention also relates to the compounds of formula (I) as defined hereinabove provided that ~~5,6 dihydrospiro[imidazo[1,2-b][3]benzazepine-11[11H],4'-piperidine]~~ 5,6 dihydrospiro[imidazo[2,1-b][3]benzazepine-11[11H],4'-piperidine] and pharmaceutically acceptable addition salts thereof are not included.

Please replace the paragraph beginning at page 7, line 30, with the following rewritten paragraph:

provided that ~~6,11-dihydro-1'-(phenylmethyl)-5H-spiro[imidazo[1,2-b][3]benzazepine-11,4'-piperidine]~~ 6,11-dihydro-1'-(phenylmethyl)-5H-spiro[imidazo[2,1-b][3]benzazepine-11,4'-piperidine] (E)-2-butenedioate(1:2) is not included.

Please replace the paragraph beginning at page 34, line 4, with the following rewritten paragraph:

A mixture of intermediate (2) (0.02 mol) in methanol (150ml) was hydrogenated with palladium on charcoal 10% (2g) as a catalyst at 50°C for 18 hours. After uptake of H_2 (1eq), the catalyst was filtered and the filtrate was evaporated, yielding 5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine] (comp. 6; not claimed). This fraction was converted into the hydrochloric acid salt (1:1) in CH_3CN, yielding 5g of ~~5,6-dihydrospiro[imidazo[1,2-b][3]benzazepine-11[11H],4'-piperidine]~~ 5,6-dihydrospiro[imidazo[2,1-b][3]benzazepine-11[11H],4'-piperidine] monohydrochloride (86%) (comp. 6a; not claimed). A fraction obtained in said way, can also be converted into the (E)-2-butenedioic acid salt.